Ultra-Low-Dose Naltrexone (ULDN)

Ultra-low-dose naltrexone (ULDN) at microgram doses taken alongside opioids — the investigational concept, the thin clinical evidence, why it isn't standard care.

Framing up front. ULDN is investigational, not standard of care. The clinical evidence is thin, mostly from the mid-2000s, and never translated into an approved product. The mechanism papers most often cited to explain why it should work were retracted by PLOS ONE in 2022 for data-integrity concerns (more on this below). Some prescribers still use it off-label in specific contexts; the broader evidence base does not support routine use.

This page exists because community members ask about it. It is not a recommendation, and the page tries to match the evidence’s actual confidence level rather than the enthusiasm the protocol sometimes attracts.

ULDN is the same molecule as normal-dose naltrexone used at doses orders of magnitude smaller than LDN, typically in the microgram range rather than the milligram range. At those doses it is hypothesized to behave differently again, selectively blocking one mode of opioid-receptor signaling while leaving the analgesic mode intact, and it has been studied alongside opioids rather than after withdrawal.

This page is one of three in the naltrexone group on this site. See the parent overview for the comparison across normal-dose, LDN, and ULDN.

ULDN is not LDN. The two share a molecule and a name; they differ by roughly three orders of magnitude in dose and by what they’re doing:

LDN: 1 to 5 milligrams, taken after opioid clearance, goal is post-acute support
ULDN: roughly 1 to 100 micrograms, taken alongside opioids (including buprenorphine), goal is to modulate tolerance or withdrawal severity

If you take an LDN-sized dose (mg range) while on opioids, you can precipitate withdrawal. If you take a ULDN-sized dose (μg range) while opioid-free, you will probably feel nothing. Same molecule, very different doses, very different intended use.

Overview and clinical evidence

The most-cited clinical reports of ULDN-with-opioid all come from the mid-2000s pain-medicine literature:

Cruciani et al., J Pain Symptom Manage 2003 , case series of patients on methadone given oral naltrexone at approximately 1 μg; reported reduced methadone side effects and potentiated analgesia.
Hamann & Sloan, J Opioid Manag 2007 , small pilot RCT (n=15) of ULDN combined with intrathecal morphine at 10 μg and 100 μg twice daily; the 100 μg twice-daily arm showed the greatest analgesic improvement but the trial was underpowered (p=0.07).
Webster et al., J Pain 2006, Phase III trial of “Oxytrex” (oxycodone combined with 1 μg naltrexone per tablet, 2–4 μg/day total) in 719 chronic low-back pain patients; reported about 55% less physical dependence compared to oxycodone alone.

That is essentially the entire clinical evidence base. Oxytrex was the most-cited result and the closest thing to a translation attempt, but the product was never approved by the FDA, the developing company eventually abandoned it, and no newer human RCTs have replicated the tolerance-blunting effect in a comparable design.

Mechanism, explicitly unsettled

The mechanism story for ULDN has a real problem. The two PLOS ONE papers from the Wang & Burns group (2008 and 2009) that proposed the filamin A binding hypothesis (the most specific and frequently-cited explanation for ULDN’s selectivity) were retracted by the journal in March 2022 over data-integrity concerns. Content elsewhere that still presents the filamin A mechanism as established is citing retracted primary literature.

The earlier, broader hypothesis from the Crain & Shen group (Brain Res 2001 and earlier 1997 work) is still on the books, picomolar-to-nanomolar naltrexone selectively blocks the Gs-coupled excitatory mu-opioid receptor signal in rodent models, unmasking inhibitory analgesia and attenuating tolerance and dependence. That hypothesis remains preclinical and contested; it has not been confirmed in human imaging or receptor studies.

The phenomenology (some patients in some trials had less tolerance buildup and potentiated analgesia at microgram doses) has peer-reviewed support, mostly older. The molecular explanation is unsettled, and the most-specific proposed mechanism (filamin A) is no longer in the live literature.

Theoretical clinical applications

The applications that come up in clinical discussions of ULDN are all extrapolated from the literature above:

Reducing tolerance buildup during long-term opioid agonist therapy (the Oxytrex-style use case)
Smoothing the bottom of a Suboxone taper: the 0.5-to-0.25 mg → 0 transition, theoretically by blocking the excitatory signaling component while leaving the analgesic component active
Reducing withdrawal severity when an opioid is discontinued
Potentiating analgesia at the same opioid dose, in chronic pain settings

The first two have community discussion in recovery contexts; the last two come from pain-medicine practice. None has a large or recent RCT base in the recovery population specifically.

For 7-OH and kratom synthetics specifically

There is no published clinical literature on ULDN for kratom or 7-OH dependence. Use in this population is extrapolated from the mid-2000s pain-medicine work and from the preclinical mu-opioid-tolerance literature. That extrapolation is theoretical, not evidence-based for this specific use case.

Practical considerations

If a reader is considering this with a prescriber:

Compounding pharmacy required that can prepare microgram-range preparations, the standard 50 mg naltrexone tablet cannot be reliably cut to the μg range, and not every compounding pharmacy is equipped for liquid titration at these scales. Verify with the pharmacist before assuming.
Very few clinicians are familiar with this protocol. Pain-medicine and addiction-medicine specialists are the most likely; primary care typically is not.
Dose accuracy matters more than with LDN: a 10× dosing mistake puts you into LDN territory, and if you’re on opioids that can mean precipitated-withdrawal-style symptoms.
No insurance coverage for compounded ULDN preparations in most cases.
This site does not prescribe doses. The numbers reported in the cited clinical literature are not protocols for you to follow at home.

Evidence-level note

Putting the framing in one box:

Mechanism: unsettled. Filamin A papers retracted; Crain/Shen Gs-coupled hypothesis remains preclinical.
Clinical evidence: thin and dated. Two case reports and a small pilot RCT in the mid-2000s, plus one Phase III in chronic pain that did not translate to an approved product. No replication trials in the last decade.
Recovery-specific evidence: essentially absent. Use is extrapolated from pain-medicine work, not from recovery-population trials.
Standard of care: no. ULDN is investigational at best.
Risk profile: generally mild side effects at microgram doses, but the dosing precision required and the interaction with whatever opioid you’re on make this a tool that requires a prescriber.

Boundaries: what ULDN is not

Not LDN. Three orders of magnitude smaller, opposite timing relative to opioids, different intended use.
Not a substitute for MAT or SR-17. It’s a theoretical adjunct to opioid agonist therapy, not a substitute for it.
Not a substitute for a real taper plan. Even where the pharmacology might help smooth the bottom of a Suboxone taper, it doesn’t replace the taper itself.
Not appropriate without medical oversight. The dose accuracy required, the interaction with whatever opioid you’re on, and the potential to overshoot into LDN territory all make this a tool that needs a prescriber in the loop.
Not a hidden missing piece of recovery. ULDN sometimes attracts framing of the “mainstream medicine missed this” type. The field tried, the clinical translation didn’t hold up, and the mechanism work hasn’t survived peer review.

Where to read next

Naltrexone (Overview): the parent page comparing all three protocols.
Low-Dose Naltrexone (LDN) , the off-label milligram-range protocol used after opioid clearance.
Normal-Dose Naltrexone , the FDA-approved 50 mg oral / 380 mg Vivitrol use, with the precipitated-withdrawal safety content.
Custom Suboxone Dosing , for the actual bottom-of-taper approach that has community validation.
Telehealth Providers: most general OUD telehealth platforms will not prescribe ULDN; this is mostly pain-medicine and integrative-medicine territory. Use the comparison only if you’ve already confirmed the specific provider works with ULDN.